https://scholars.lib.ntu.edu.tw/handle/123456789/456923
標題: | A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer | 作者: | Tsai C.-H. Tzeng S.-F. Hsieh S.-C. Yang Y.-C. Hsiao Y.-W. Tsai M.-H. Hsiao P.-W. MONG-HSUN TSAI |
公開日期: | 2017 | 卷: | 7 | 期: | 1 | 來源出版物: | Scientific Reports | 摘要: | Activation of the NFκB pathway is often associated with advanced cancer and has thus been regarded as a rational therapeutic target. Wedelia chinensis is rich in luteolin, apigenin, and wedelolactone that act synergistically to suppress androgen receptor activity in prostate cancer. Interestingly, our evaluation of a standardized Wedelia chinensis herbal extract (WCE) concluded its efficacy on hormone-refractory prostate cancer through systemic mechanisms. Oral administration of WCE significantly attenuated tumor growth and metastasis in orthotopic PC-3 and DU145 xenografts. Genome-wide transcriptome analysis of these tumors revealed that WCE suppressed the expression of IKKα/β phosphorylation and downstream cytokines/chemokines, e.g., IL6, CXCL1, and CXCL8. Through restraining the cytokines expression, WCE reduced tumor-elicited infiltration of myeloid-derived suppressor cells (MDSCs), tumor-Associated macrophages (TAMs) and endothelial cells into the tumors, therefore inhibiting angiogenesis, tumor growth, and metastasis. In MDSCs, WCE also reduced STAT3 activation, downregulated S100A8 expression and prevented their expansion. Use of WCE in combination with docetaxel significantly suppressed docetaxel-induced NFκB activation, boosted the therapeutic effect and reduced the systemic toxicity caused by docetaxel monotherapy. These data suggest that a standardized preparation of Wedelia chinensis extract improved prostate cancer therapy through immunomodulation and has potential application as an adjuvant agent for castration-resistant prostate cancer. ? 2017 The Author(s). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/456923 | ISSN: | 20452322 | DOI: | 10.1038/s41598-017-15934-0 | SDG/關鍵字: | antineoplastic agent; docetaxel; immunoglobulin enhancer binding protein; plant extract; animal; apoptosis; cell proliferation; chemistry; drug effect; drug screening; gene expression regulation; genetics; human; inflammation; macrophage; male; mouse; neovascularization (pathology); pathology; phosphorylation; prostate tumor; tumor cell line; Wedelia; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Macrophages; Male; Mice; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Plant Extracts; Prostatic Neoplasms; Wedelia; Xenograft Model Antitumor Assays |
顯示於: | 生物科技研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。